Institution
University of Modena and Reggio Emilia
Education•Modena, Italy•
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.
Topics: Population, Medicine, Cancer, Context (language use), Computer science
Papers published on a yearly basis
Papers
More filters
••
TL;DR: On-line HPLC-ESI/MS analysis constitutes an alternative to obtain typical fingerprints of propolis and a reliable identification of a large number of propoli polyphenolic components.
142 citations
•
Catholic University of the Sacred Heart1, University of Pavia2, Sapienza University of Rome3, University of Bari4, University of Palermo5, University of Naples Federico II6, University of Ferrara7, University of Florence8, University of Genoa9, University of Siena10, Marche Polytechnic University11, University of Verona12, University of Modena and Reggio Emilia13, University of Perugia14
TL;DR: It is shown that only a minority of patients with longstanding RA achieve a good clinical response or remission at the outpatient community level and predictors of remission identify characteristics commonly observed in subsets with less severe RA.
Abstract: OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ). Those who had improved by at least 0.25 HAQ were analyzed for possible predictors of DAS28 remission at the sixth month. RESULTS: A total of 1257 patients started TNF-alpha blockers. Of these, 591 (46.7%) reached the sixth month with an improvement of HAQ of 0.25 at the third month. In the cohort of patients reaching HAQ of 0.25, DAS28 remission was seen in 24% of rheumatoid factor (RF)-positive and 36% of RF-negative patients (p = 0.03). Logistic regression analysis for predictors of remission identified age at baseline, HAQ
142 citations
••
TL;DR: In this paper, a Holey fiber with very complex hole geometry is studied by means of a numerical simulator for modal analysis based on the finite element method (FEM) and the results show a good agreement with experimental ones reported in literature.
Abstract: A holey fiber (HF), having very complex hole geometry, is studied by means of a numerical simulator for modal analysis based on the finite-element method (FEM). Polarization and dispersion properties as well as the full vector field distribution of the fundamental mode are investigated. The obtained numerical results show a good agreement with experimental ones reported in literature.
142 citations
••
University of Tübingen1, Catholic University of the Sacred Heart2, University of Kiel3, Charles University in Prague4, Odense University Hospital5, King's College London6, Université libre de Bruxelles7, University of Nantes8, University of L'Aquila9, Aix-Marseille University10, Medical University of Vienna11, Goethe University Frankfurt12, Aristotle University of Thessaloniki13, Saint Louis University Hospital14, University of Oxford15, University of Modena and Reggio Emilia16, Versailles Saint-Quentin-en-Yvelines University17, National and Kapodistrian University of Athens18, University of Trieste19
TL;DR: Recommendations on cutaneous melanoma diagnosis and treatment are made based on systematic literature reviews and the experts' experience, and it is likely that these recommendations may change in the near future.
142 citations
••
University of Bologna1, University of Antwerp2, National Research Council3, University of Modena and Reggio Emilia4, University of Regensburg5, Georgia Regents University6, University of Pittsburgh7, University of Bern8, University of Madras9, Rutgers University10, University of Zurich11, Celgene12, University of South Florida13
TL;DR: The international workshop held in Brescia, Italy, in March 2009 aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases.
Abstract: Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled "Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application" was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.
141 citations
Authors
Showing all 8322 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo M. Croce | 198 | 1135 | 189007 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Peter M. Rothwell | 134 | 779 | 67382 |
Claudio Franceschi | 120 | 856 | 59868 |
Lorenzo Galluzzi | 118 | 477 | 71436 |
Leonardo M. Fabbri | 109 | 566 | 60838 |
David N. Reinhoudt | 107 | 1082 | 48814 |
Stefano Pileri | 100 | 635 | 43369 |
Andrea Bizzeti | 99 | 1168 | 46880 |
Brian K. Shoichet | 98 | 281 | 40313 |
Dante Gatteschi | 97 | 727 | 48729 |
Roberta Sessoli | 95 | 424 | 41458 |
Thomas A. Buchholz | 93 | 494 | 33409 |
Pier Luigi Zinzani | 92 | 857 | 35476 |